SHP1705 synergizes with novel REV-ERB agonist SR29065. (A) GSC 387, (B) DGC 387, (C) GSC 3565, (D) DGC 3565, (E) MGG 4, (F) DGC 4, (G) MGG 31, or (H) DGC 31 was handled with each SHP1705 and SR29065 for 4 days (n = 3–4 biologically unbiased samples). Cell viability outcomes have been plotted with SynergyFinder3.0. Credit score: Neuro-Oncology (2025). DOI: 10.1093/neuonc/noaf089
A sequence of preclinical research present {that a} new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the most cancers cells’ means to outlive and develop. SHP1705 can be the primary clock-targeting compound to finish a section 1 medical trial, the place it was discovered to be protected and well-tolerated in people. A abstract of the analysis is revealed within the journal Neuro-Oncology.
Glioblastoma is the most typical cancerous mind tumor in adults—and one of the crucial tough to deal with. Most sufferers obtain a mix of surgical procedure, radiation and chemotherapy, however tumors usually return and resist additional therapy.
Circadian clock proteins, which regulate the physique’s sleep-wake cycle and different day by day rhythms on the mobile stage, supply a possible resolution. Glioblastoma cells hijack these proteins with a purpose to replicate, so switching them off might gradual or halt tumor progress.
“We have mounting evidence that clock proteins can be co-opted by brain cancer stem cells to fuel their growth,” mentioned the research’s senior creator, Steve A. Kay, Ph.D., College and Provost Professor of Neurology, Biomedical Engineering and Quantitative Computational Biology and co-director of the USC Norris Heart for Most cancers Drug Growth on the Keck College of Medication of USC. “If we can successfully target the circadian clock, these cells lose their ability to replicate.”
Kay and Jeremy Wealthy, MD, of the College of North Carolina at Chapel Hill, oversee a global analysis staff that’s growing a drug to focus on the hijacked circadian clock proteins. By way of a sequence of biochemical, mobile and animal research, the researchers examined SHP1705’s means to neutralize glioblastoma stem cells, discovering it to be extremely efficient. A section 1 medical trial led by Synchronicity Pharma, a biotechnology startup that Kay co-founded, confirmed that SHP1705 was well-tolerated in people.
In comparison with the staff’s earlier research of clock-targeting compounds, SHP1705 is stronger and a greater match for glioblastoma, Kay mentioned.
Focusing on glioblastoma cells
SHP1705 is called a CRY activator as a result of it will increase the exercise of cryptochrome (CRY) proteins inside cells. CRY proteins then inhibit the cell’s circadian clock equipment.
Not like earlier CRY activators studied by Kay’s staff, SHP1705 particularly targets a model of the CRY protein generally known as CRY2. CRY2 ranges are unusually low in glioblastoma cells, making these cells extra aware of makes an attempt to reactivate the protein. By boosting CRY2 exercise in glioblastoma cells, SHP1705 helps shut down the most cancers cells’ circadian clock equipment, whereas leaving wholesome mind cells—the place CRY2 is already energetic—largely unaffected.
The researchers carried out a sequence of preclinical research that examined SHP1705’s means to battle glioblastoma stem cells, that are thought to drive tumor progress and recurrence. They discovered that SHP1705 impaired most cancers stem cells’ means to outlive, with minimal influence on wholesome cells. Once they handled glioblastoma stem cells with different compounds developed to focus on clock proteins, none labored in addition to SHP1705.
The checks included two traces of glioblastoma stem cells: one aware of temozolomide (chemotherapy) therapy and one immune to it. SHP1705 focused each, suggesting it could possibly be efficient towards most cancers cells that return after preliminary therapy. Mouse research additional confirmed SHP1705’s potential, displaying {that a} increased dose slowed tumor progress and prolonged survival. In mice, SHP1705 additionally made most cancers cells extra more likely to die after radiation therapy.
Combining SHP1705 with SR29065, a compound focusing on one other a part of the circadian clock that was developed by Kay’s collaborators on the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Expertise, produced even higher leads to a number of checks.
“The synergy we observed between these two compounds also shows great potential,” Kay mentioned.
Lastly, Synchronicity Pharma carried out a section 1 medical trial with 54 wholesome volunteers, discovering that SHP1705 was well-tolerated, with solely minor unintended effects corresponding to headache and nausea.
Testing SHP1705 with sufferers
The following step is a section 2 medical trial, the place SHP1705 can be examined alongside present therapies: surgical procedure, chemotherapy and radiation. The compound will be taken as a tablet, so it provides minimal burden to sufferers already present process intensive therapy.
“Right now, the current standard of care does not address glioblastoma stem cells that drive the cancer’s recurrence,” Chan mentioned. “Our hope is that SHP1705 can help close that gap.”
Hijacked clock proteins not solely play a job in glioblastoma stem cell replication, however seem to gas tumor progress in different methods. Analysis suggests they assist suppress immune cell exercise and promote blood vessel progress to help the tumor. Kay, Chan and their staff are actually investigating methods to additional goal these proteins.
Extra info:
Priscilla Chan et al, Advancing medical response towards glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical fashions and security in section I trials, Neuro-Oncology (2025). DOI: 10.1093/neuonc/noaf089
Supplied by
Keck College of Medication of USC
Quotation:
Experimental compound targets circadian clock equipment in cells to battle glioblastoma (2025, Might 12)
retrieved 13 Might 2025
from https://medicalxpress.com/information/2025-05-experimental-compound-circadian-clock-machinery.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
